Why Clinical Laboratories Are Launching Direct-to-Consumer Testing in 2026

For decades, most clinical laboratories operated primarily behind the healthcare system.

A physician ordered the test. A patient visited a collection site. The laboratory performed the analysis. Results moved back through the ordering provider or patient portal.

That model remains fundamental to healthcare.

But it is no longer the only way consumers interact with laboratory testing.

Consumers can now purchase many laboratory tests online, complete collection at a nearby location or in some cases at home, and receive results digitally. Quest currently offers more than 150 tests for online consumer purchase through Quest Health, while Labcorp OnDemand offers consumer-purchased testing across in-person and at-home collection models.

The Association for Diagnostics & Laboratory Medicine has described consumer-initiated testing models as growing alongside advances in digital technology and supports expanded consumer access to appropriately performed direct-to-consumer laboratory testing.

For established laboratories, the strategic question is therefore changing.

It is no longer only:

Should consumers be able to access laboratory testing directly?

It is increasingly:

Should our laboratory own the consumer relationship around the testing infrastructure we already operate?

That is the business case behind the shift toward direct-to-consumer laboratory testing.

The short answer: Why are laboratories launching DTC testing?

Established clinical laboratories are exploring direct-to-consumer testing because it can create:

• a new cash-pay revenue channel;
• a direct relationship with consumers;
• greater utilization of existing laboratory infrastructure;
• more control over brand, pricing, and consumer experience;
• opportunities for repeat and longitudinal testing;
• less dependence on a purely provider-mediated acquisition model;
• a way to compete with consumer-health companies entering diagnostics.

At the same time, consumers increasingly expect easier digital access to testing, collection, and results. Major national laboratories now operate their own consumer-purchased testing channels, reinforcing that DTC is no longer limited to startups or niche wellness companies.

But DTC is not automatically profitable, operationally simple, or appropriate for every laboratory.

The laboratories most likely to create durable value are those that treat DTC as a new operating and distribution model, not simply an online store.

1. Laboratories already own the hardest part of the business

For an established laboratory, one of the strongest arguments for DTC is structural.

The laboratory may already have:

• testing infrastructure;
• instrumentation;
• laboratory personnel;
• quality systems;
• CLIA certification;
• LIS/LIMS infrastructure;
• accessioning;
• test menus;
• specimen-processing workflows;
• collection locations;
• courier relationships;
• result-generation systems;
• compliance processes.

CMS continues to regulate human laboratory testing through CLIA with the objective of ensuring accurate, reliable, and timely test results.

For an existing laboratory, much of this regulated clinical infrastructure is already operating.

That means launching DTC does not necessarily require creating another laboratory.

The strategic opportunity is to add a consumer distribution and operating layer around the infrastructure that already exists.

In simplified form:

This is fundamentally different from a consumer-health startup that must first find laboratory partners capable of performing the actual testing.

The established laboratory starts with the clinical asset already in place.

2. DTC creates another revenue channel

Traditional laboratory economics can involve reimbursement processes, contracted rates, provider referrals, health-plan relationships, institutional clients, and significant billing complexity.

Consumer-paid testing creates a different transaction.

The consumer selects testing and pays for the service directly within the applicable ordering model.

Quest Health currently markets consumer-purchased testing without requiring health insurance, while Labcorp OnDemand allows consumers to purchase testing online before completing collection.

For laboratories, that creates the possibility of adding a cash-pay revenue channel alongside existing business, rather than relying exclusively on traditional reimbursement and referral models.

That does not mean cash-pay revenue is automatically more profitable.

A consumer order introduces its own costs:

• payment processing;
• collection;
• provider authorization where required;
• customer support;
• marketing;
• refunds;
• recollections;
• technology;
• fulfillment.

The strategic advantage is revenue diversification, not the elimination of operating cost.

A laboratory with a strong test catalog, available capacity, efficient collection, and existing market presence may be able to monetize infrastructure in ways that were difficult when every testing relationship originated through another healthcare organization.

3. DTC gives laboratories a direct consumer relationship

In the traditional model, laboratories frequently have limited control over how consumers discover testing.

The relationship may primarily belong to:

• the physician;
• the health system;
• the employer;
• the insurer;
• another consumer-health company.

The laboratory performs the testing but can remain largely invisible.

DTC changes that relationship.

A laboratory can potentially own:

the brand
the discovery experience
the catalog
the pricing
the transaction
the collection experience
the results experience
the ongoing relationship

That matters strategically.

The first transaction creates something many laboratories historically have not had:

a direct commercial relationship with the individual whose specimen they are testing.

That relationship can become more valuable over time if the laboratory provides a useful experience beyond the original transaction.

For Solia Direct, this is a core architectural principle: the laboratory retains its brand, domain, catalog, pricing, and customer relationship while the platform sits between the consumer experience and existing laboratory infrastructure.

4. Consumer expectations around testing are changing

The demand side matters as much as laboratory economics.

Consumer-initiated testing reduces several sources of friction that can exist in traditional healthcare access.

Depending on the test and applicable ordering rules, consumers may be able to:

• discover testing online;
• purchase without scheduling a traditional physician appointment;
• choose a convenient collection option;
• access results digitally;
• review prior testing;
• take a more active role in monitoring health information.

ADLM supports expanded access to consumer-initiated laboratory testing when testing is appropriately performed and accompanied by clear information about purpose, collection, limitations, results, and cost.

Major diagnostic companies are already serving this behavior.

Quest Health currently allows consumers to browse and purchase more than 150 laboratory tests online. Labcorp OnDemand offers both in-person and at-home consumer-purchased testing and promotes direct digital access to results.

That does not prove every patient wants every laboratory test without provider involvement.

It demonstrates that consumer-initiated diagnostics is now an established distribution model inside mainstream laboratory medicine.

5. Major laboratories have validated the model

One reason established laboratories are paying more attention to DTC is simple:

Large diagnostic companies are already doing it.

Quest Diagnostics operates Quest Health, a dedicated consumer channel through which individuals can purchase laboratory tests online.

Labcorp operates Labcorp OnDemand, allowing consumers to purchase laboratory testing directly and complete either in-person or selected at-home collection workflows.

This matters competitively.

DTC is no longer a strategy available only to venture-backed health startups that outsource laboratory testing.

The laboratory itself can become the consumer brand.

For regional and specialty laboratories, that raises a more immediate strategic question:

If national laboratories can build direct consumer channels around their existing testing infrastructure, why should the consumer relationship automatically belong to someone else?

The answer will differ by laboratory.

But the category has already been validated by some of the industry's largest operators.

6. Laboratories can compete more directly with consumer-health brands

Over the last several years, consumers have become increasingly familiar with diagnostics sold as part of a broader health experience.

These companies often compete on:

• brand;
• convenience;
• digital experience;
• test curation;
• education;
• memberships;
• longitudinal tracking;
• consumer acquisition.

The laboratory underneath may still perform the clinical testing.

That creates an unusual competitive dynamic.

The organization owning the clinical infrastructure may capture only one part of the consumer value chain, while another company owns:

the brand + the customer + the transaction + the ongoing relationship.

DTC gives laboratories the opportunity to move further up that value chain.

Instead of functioning only as the testing backend, an established laboratory can potentially operate:

its own catalog
its own consumer experience
its own commercial model
its own ongoing patient relationship

while still relying on the same clinical infrastructure.

This does not mean laboratories should attempt to become lifestyle brands.

It means they can decide whether the consumer relationship itself is strategically valuable enough to own.

7. DTC can turn isolated testing into a longitudinal relationship

Laboratory testing naturally produces structured measurements over time.

Traditional consumer experiences often treat each laboratory encounter as an isolated event.

A test is ordered.

A result is generated.

The interaction ends.

But many legitimate laboratory use cases involve measurement over time.

For example:

Baseline → intervention → retest → compare

or:

January → April → August

A direct consumer relationship creates the opportunity to make those separate testing events part of a longitudinal experience.

That can support:

• historical results;
• biomarker trends;
• repeat testing;
• testing reminders where appropriate;
• structured monitoring programs;
• persistent consumer accounts;
• longitudinal health records around laboratory data.

The objective should not be to encourage unnecessary testing.

ADLM specifically emphasizes appropriate test use, understandable interpretation, and professional guidance where needed.

The commercial opportunity exists where repeat testing is both appropriate and useful.

That is materially different from optimizing only for another ecommerce transaction.

8. DTC can make better use of existing laboratory capacity

A laboratory's physical and clinical infrastructure has substantial fixed cost.

Facilities, instruments, systems, personnel, compliance programs, collection locations, and support functions already exist regardless of whether every unit of potential capacity is used.

That creates a strategic possibility.

If a laboratory can add profitable incremental consumer volume without compromising its existing clinical operation, DTC may improve the utilization of infrastructure that is already being funded.

The exact economics vary significantly by laboratory.

Available capacity does not automatically equal profitable capacity.

Additional consumer volume may also create:

• collection bottlenecks;
• staffing needs;
• support demand;
• additional interface volume;
• operational exceptions.

But the existing laboratory starts with an important asset:

it does not have to recreate the testing infrastructure for every new consumer channel.

The question becomes whether the incremental consumer contribution justifies the incremental commercial and operational cost.

That question is addressed separately in:

9. Digital infrastructure now makes the model more practical

A DTC laboratory channel requires coordination across systems that historically were often disconnected.

The consumer expects one experience.

Behind that experience may be:

• commerce;
• payments;
• ordering;
• provider authorization;
• identity;
• scheduling;
• collection;
• LIS/LIMS;
• specimen workflow;
• results;
• communications.

Modern APIs, healthcare interoperability standards, payment infrastructure, identity systems, and consumer software make it increasingly practical to connect these components.

The strategic architecture is therefore becoming:

Consumer experience
↓
Consumer operating layer
↓
Integration layer
↓
Existing laboratory infrastructure

rather than:

replace every laboratory system with a new DTC system.

Solia Direct is designed around this separation. It sits above existing LIS/LIMS, scheduling, collection, payment, and clinical systems, with the laboratory remaining authoritative for official results.

This is important because many established laboratories do not need another LIS.

They need a better way to expose the capabilities of the laboratory to consumers.

Traditional laboratory model vs. DTC channel

The two models are not mutually exclusive.

For most established laboratories, DTC is better understood as an additional channel, not a replacement for provider or institutional business.

The strongest laboratory strategy may support both.

DTC does not require abandoning the traditional clinical channel.

It gives the laboratory another way to reach the market.

DTC does not necessarily mean bypassing physicians

One of the most persistent misconceptions about direct-to-consumer laboratory testing is that every DTC test is ordered entirely without clinician involvement.

That is not correct.

CMS distinguishes laboratory regulation under CLIA from the state-level question of who may legally order a laboratory test. CMS notes that some states do not permit unrestricted direct-access testing and that state law may determine who qualifies as an authorized person for ordering purposes.

A DTC consumer experience can therefore support several operating models:

• consumer self-ordering where legally permitted;
• provider-authorized ordering;
• integrated telehealth or ordering-provider review;
• different workflows according to test and jurisdiction.

Labcorp OnDemand, for example, states that an independent physician reviews and approves certain consumer test requests even though no traditional physician visit is required for the consumer purchase flow.

The important distinction is between:

consumer-initiated

and

clinically ungoverned.

They are not the same thing.

The opportunity does not eliminate the risks

There are good reasons laboratories are exploring DTC.

There are equally good reasons not to treat it as easy money.

Several failure points deserve particular attention.

Regulatory complexity

Ordering authority and direct-access rules can vary by state.

A national consumer storefront cannot simply assume that every product can be sold through the same workflow everywhere. CMS explicitly notes the role of state law in determining authorized ordering and access.

Consumer misunderstanding

Laboratory results can be difficult to interpret without context.

ADLM recommends that DTC testing providers clearly explain the test's purpose, appropriate use, specimen-collection process, limitations, interpretation, and cost, and emphasizes access to professional guidance where appropriate.

A better consumer interface does not remove the need for clinical responsibility.

Customer acquisition can be expensive

Launching a website does not create demand.

A laboratory without existing consumer awareness may have to compete for attention through:

• search;
• paid media;
• partnerships;
• employers;
• provider relationships;
• content;
• local brand awareness.

A technically successful DTC launch can still fail commercially if acquiring each new consumer costs more than the order contributes.

Collection can break the experience

A consumer can complete checkout in seconds.

Collecting a valid clinical specimen is considerably more complicated.

The consumer model still depends on reliable:

• scheduling;
• identification;
• preparation;
• collection;
• specimen handling;
• transportation;
• accessioning.

Digital commerce does not change specimen biology.

Operational fragmentation can destroy margins

If commerce, collection, LIS/LIMS, results, payments, and support do not share reliable workflow states, staff may be forced to reconcile orders manually.

At small volume, this may be tolerable.

At scale, it becomes an operational cost center.

Not every laboratory should launch DTC

The fact that DTC is strategically interesting does not mean every laboratory should pursue it.

A laboratory should be cautious if:

• it has no clear consumer audience;
• margins cannot support the variable cost structure;
• collection coverage is weak;
• operational capacity is already constrained;
• LIS/LIMS integration would require extensive manual work;
• there is no owner for the consumer business;
• leadership views DTC only as a website project;
• there is no credible consumer-acquisition strategy.

The technology is not the business case.

The business case has to exist independently.

A laboratory should be able to answer:

Who will buy?
Why will they buy from us?
What will we sell?
How will collection work?
What will one completed order contribute?
How will the consumer experience connect to laboratory operations?
Why are we better positioned to own this relationship than someone else?

If those answers are weak, adding DTC software will not fix the strategy.

What established laboratories have that startups often do not

There is another way to understand why laboratories are moving toward DTC.

Compare the assets required to create a consumer diagnostics company.

A startup may need to secure:

• laboratory capacity;
• testing agreements;
• collection;
• clinical infrastructure;
• ordering-provider relationships;
• result delivery;
• logistics;
• regulatory expertise.

An established laboratory may already control much of that stack.

What it often lacks is:

• consumer commerce;
• modern digital UX;
• direct acquisition;
• consumer workflow orchestration;
• longitudinal engagement;
• consumer-focused administration.

That is a narrower gap to close.

The strategic thesis is therefore:

Established laboratories do not need to become consumer-health startups.

They can add consumer infrastructure around what they already do exceptionally well:

laboratory testing.

What has to be true for DTC to work?

A durable DTC model generally requires four things to be true at the same time.

1. The consumer proposition has to be compelling

The test, panel, program, convenience, price, or experience must provide a reason for someone to choose the laboratory directly.

2. The unit economics have to work

Revenue has to support testing, collection, authorization where applicable, payments, support, acquisition, technology, and operational exceptions.

3. The workflow has to work

The digital order must reliably become:

the right patient
the right specimen
the right laboratory test
the right official result.

4. The laboratory has to want the relationship

Operating a consumer channel means accepting responsibilities that may previously have sat elsewhere:

• merchandising;
• support;
• payments;
• consumer communications;
• retention;
• digital experience.

DTC is strategically valuable when the laboratory actually wants to own those responsibilities and the relationship they create.

Why 2026 matters

There is nothing magical about the calendar year itself.

The significance of 2026 is that several conditions now coexist.

Consumer-initiated testing is supported as a legitimate access model by a major professional laboratory organization when appropriate safeguards are present.

National diagnostic companies have established consumer-purchased laboratory channels rather than leaving the category exclusively to startups.

Digital infrastructure increasingly allows the consumer layer to connect to existing clinical infrastructure rather than requiring the laboratory to rebuild its core systems.

And consumers have become accustomed to discovering, purchasing, scheduling, managing, and accessing services digitally across nearly every other category.

Taken together, those conditions make DTC less of an experiment and more of a strategic channel that established laboratories need to at least evaluate.

Frequently asked questions

Why are clinical laboratories launching direct-to-consumer testing?

Clinical laboratories are exploring DTC to create direct cash-pay revenue, establish direct consumer relationships, better utilize existing laboratory infrastructure, offer more convenient access to testing, and create opportunities for repeat and longitudinal engagement. National laboratories including Quest and Labcorp now operate consumer-purchased testing channels.

Why is direct-to-consumer laboratory testing growing?

Consumer-initiated testing has become easier to deliver through digital ordering, modern collection models, online payments, and digital results. ADLM has noted that consumer-initiated testing models have grown alongside increased digital access and supports expanded consumer access when appropriate laboratory quality, information, and guidance are maintained.

What are the benefits of DTC testing for laboratories?

Potential benefits include revenue diversification, direct customer ownership, better use of existing infrastructure, stronger consumer branding, repeat-testing opportunities, and reduced dependence on exclusively provider-mediated acquisition. Whether those benefits produce a profitable business depends on the laboratory's cost structure, collection model, operations, and customer-acquisition economics.

Is direct-to-consumer lab testing more profitable than traditional laboratory testing?

Not necessarily. DTC can create direct cash-pay revenue, but it also introduces consumer acquisition, payment processing, collection, provider-authorization, support, technology, refund, and recollection costs. Profitability has to be measured at the completed-order level rather than assumed from retail price.

Can consumers order their own laboratory tests?

In some circumstances, yes, but the applicable ordering model depends on the test and jurisdiction. CMS notes that state law can determine who is authorized to order testing and that some states restrict direct access.

Does DTC testing eliminate physicians from the process?

No. Some DTC models allow direct access where permitted, while others incorporate provider review or authorization. Consumer initiation and provider involvement can coexist within the same laboratory workflow.

Are Quest Diagnostics and Labcorp offering direct-to-consumer testing?

Yes. Quest operates Quest Health, where consumers can purchase more than 150 laboratory tests online, and Labcorp operates Labcorp OnDemand for consumer-purchased in-person and selected at-home testing.

Does a laboratory need a new LIS to launch DTC?

Not necessarily. A DTC consumer layer can be integrated with existing LIS/LIMS and clinical infrastructure rather than replacing the systems responsible for laboratory testing and official results. Solia Direct is specifically designed around this architecture.

Should every established clinical laboratory launch DTC?

No. DTC makes the most sense when the laboratory has a credible consumer proposition, workable unit economics, reliable collection, integration capability, operational capacity, and a strategic reason to own the consumer relationship.

The strategic opportunity for established laboratories

The most important reason laboratories are moving toward direct-to-consumer testing is not that consumers suddenly discovered laboratory medicine.

It is that the relationship around laboratory medicine is changing.

Consumers can increasingly initiate the journey themselves.

Major laboratories have already built channels to serve them directly.

Digital infrastructure makes it possible to connect that consumer experience to the clinical systems underneath.

And established laboratories already possess the asset at the center of the entire model:

the ability to perform the testing.

The opportunity is to build around that asset.

Discovery → Commerce → Collection → Testing → Results → Longitudinal relationship

For some laboratories, DTC will remain a small complementary channel.

For others, it can become a significant new line of business.

The deciding factor will not be whether a laboratory can put tests online.

It will be whether the laboratory can turn its existing clinical infrastructure into a consumer business that is useful, operationally reliable, compliant, and economically sustainable.

Where Solia Direct fits

Solia Direct is designed for established laboratories that already own or operate the clinical infrastructure but need the consumer operating layer around it.

The platform connects:

Consumer Commerce
→ Scheduling & Collection
→ Patient Accounts
→ Workflow Orchestration
→ Results & Longitudinal Health
→ Intelligence
→ Admin & Operations

to existing laboratory infrastructure through APIs, HL7/FHIR, adapters, scheduling, collection, payments, and other integrations.

The laboratory remains the clinical source of truth and retains control of its brand, domain, catalog, pricing, and customer relationship.

For laboratories moving from strategic interest to execution:

For laboratories evaluating software:

For laboratories evaluating the economics:

To see the model in practice:

Sources and references

1. Centers for Medicare & Medicaid Services — Direct Access Testing and the CLIA Regulations. CMS guidance addressing direct-access testing, CLIA, and the role of state law in determining ordering authority.
2. Centers for Medicare & Medicaid Services — Clinical Laboratory Improvement Amendments. Current federal overview of CLIA and laboratory quality requirements.
3. Association for Diagnostics & Laboratory Medicine — Direct-to-Consumer Laboratory Testing Position Statement. Current professional position supporting appropriate consumer access while emphasizing laboratory quality, understandable information, interpretation, and state requirements.
4. ADLM — Consumer-Initiated Testing and Access to Care. Discussion of the growth of consumer-initiated testing alongside digital technology and patient-centered collection models.
5. Quest Health. Current consumer laboratory channel offering online purchase of more than 150 laboratory tests.
6. Labcorp OnDemand. Current consumer testing channel supporting online test purchase with in-person and selected at-home collection.
7. Solia Direct — Direct-to-Consumer Testing. Current product architecture and laboratory-ownership model for DTC deployments.
8. Solia Direct — Platform. Current platform architecture connecting the consumer operating layer to existing laboratory infrastructure.